Form 4: ChromaDex CEO Awarded 1,518,600 Performance Stock Units

ChromaDex Corp. CEO Robert N. Fried was granted 1,518,600 performance stock units (PSUs) on February 25, 2025, which vest upon achieving specific stock price targets and continued employment.

Summary

• Robert N. Fried, CEO of ChromaDex Corp., was granted 1,518,600 Performance Stock Units (PSUs) on February 25, 2025.
• Each PSU represents a contingent right to receive one share of ChromaDex's common stock when vested.
• The PSUs vest incrementally upon the company's common stock achieving specified price per share performance goals and continued employment prior to February 25, 2032, and are subject to a change in control.
• The reporting person directly owns 1,518,600 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management incentives with shareholder value. The sentiment is slightly positive due to the performance-based nature of the grant.

Positives

• The performance-based vesting of the PSUs aligns the CEO's interests with those of the shareholders, incentivizing stock price appreciation.
• The long vesting period (until February 25, 2032) encourages long-term commitment from the CEO.

Risks

• The vesting of the PSUs is contingent on achieving specific stock price targets, which may not be met.
• The CEO's continued employment is required for the PSUs to vest, creating potential risk if the CEO leaves the company before February 25, 2032.

Future Outlook

The document does not contain any specific forward-looking statements or guidance beyond the vesting schedule of the PSUs.

Industry Context

Granting performance-based equity compensation is a common practice in the industry to align executive incentives with shareholder value creation. The specific terms of the PSU grant, such as the performance targets and vesting schedule, are tailored to ChromaDex's specific circumstances and strategic goals.

Comparison to Industry Standards

• Performance-based equity compensation is a common practice among publicly traded companies, particularly in the biotechnology and consumer health sectors.
• Comparable companies like Herbalife Nutrition and Nu Skin Enterprises also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules and performance metrics associated with these grants vary depending on the company's size, growth stage, and strategic priorities.

Stakeholder Impact

• Shareholders: The PSU grant is intended to incentivize the CEO to increase shareholder value through stock price appreciation.
• Employees: The PSU grant may have a positive impact on employee morale by aligning the CEO's interests with the company's overall success.

Key Dates